EB
Therapeutic Areas
Sentynl Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ZYCUBO® (copper histidinate) | Likely Menkes disease or related copper deficiency disorder (based on drug name) | Approved |
Leadership Team at Sentynl Therapeutics
MH
Matt Heck
Founder, Chief Executive Officer & Director
MH
Michael Hercz, Esq.
Executive Vice President, Chief Legal & Compliance Officer
JR
Jennifer Reese, PharmD
Senior Vice President Medical Affairs
GW
Grant W. Castor
Executive Vice President, Chief Business & Commercial Officer